Biotechnology
Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization
* Process Performance Qualification (PPQ) validates robust manufacturing standards and is crucial for regulatory compliance * Marks a key step forward for the world's first once-monthly IL-4Rα-targeting antibody therapeutic for Th2-driven diseases, with a strategic focus on entering the Ameri...
2025-01-03 21:15
2977
GRIT Bio Appoints Jie Jia, Ph.D., as Chief Operating Officer
SHENZHEN, China, Jan. 3, 2025 /PRNewswire/ -- Shenzhen GRIT Biotechnology Co., Ltd., a leading company in cell therapy globally, today announced the appointment ofJie Jia, Ph.D., as Chief Operating Officer (COO), effective on the date of this press release. Dr. Jia, Jie brings over 20 years of...
2025-01-03 15:30
1981
Nona Biosciences Announces Update on Its Collaborator DualityBio's Antibody-Drug Conjugate (ADC) Collaboration with BeiGene
CAMBRIDGE, Mass., Jan. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced that BeiGene. Ltd. has exercised its exclusive option to acquire global development, manufacturing, and commercialization right...
2025-01-03 13:30
1417
Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044
WUHAN, China, Jan. 2, 2025 /PRNewswire/ -- Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical need diseases, today announced the first patient dosing inAustralia on Dec 30, 2024 for Phase 1 cl...
2025-01-03 01:43
1731
WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year
* Named for second consecutive year named to prestigious DJSI list * Leading green biologics solutions for a healthier future SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), t...
2025-01-02 17:30
1515
Fapon Biopharma Introduces FP008 at Biotech Showcase: A Safer and More Effective Immunotherapy for Refractory Cancers
SAN FRANCISCO, Jan. 2, 2025 /PRNewswire/ -- Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, will present its latest breakthrough immunocytokine, FP008, onJan 14, 2025, at the Biotech Showcase investor conference, following J.P. Morgan Healthcare Week. This ...
2025-01-02 17:17
910
FDA Grants Orphan Drug Designation to MicuRx's MRX-5 for NTM Infections
SHANGHAI, Jan. 1, 2025 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx"，688373.SH) announced that MRX-5, its self-developed anti-infection drug, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment ofnon-tuberculous myco...
2025-01-02 12:52
1608
CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy
SHANGHAI, Dec. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the initiation of an investigator-initiated trial (IIT) inChina for K...
2024-12-31 21:50
2725
Ractigen Therapeutics Founder Dr. Long-Cheng Li Awarded 2024 Life Science Ice Breaking Award
NANTONG and SUZHOU, China, Dec. 31, 2024 /PRNewswire/ -- Ractigen Therapeutics proudly announces that its Founder and CEO, Dr.Long-Cheng Li, has been honored with the 2024 Life Science Ice Breaking Award. This award, established by Mr. Cai Lei, a prominent ALS patient and advocate, along with his ...
2024-12-31 20:00
1793
Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene
SOMERSET, N.J., SHANGHAI and SUZHOU, China, Dec. 30, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio") announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074 from DualityBio, securing global development, manufacturing, and ...
2024-12-31 08:00
1596
I Peace manufactures 100 lines of GMP iPS Cells cumulatively
Proof of customer recognition of its quality and mass manufacturing capability
PALO ALTO, Calif., Dec. 30, 2024 /PRNewswire/ -- Leading GMP cell CDMO I
Peace, Inc. (https://ipeace.com/en/
2024-12-31 04:24
1022
Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SEONGNAM, South Korea and BOSTON, Dec. 30, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that James Jungkue Lee, Founder and CEO of Bridge Biotherapeutics, will present ...
2024-12-30 23:00
2079
CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)
SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the positive results from the pivotal Phase II clinical trial CT041-...
2024-12-30 21:50
1953
WuXi AppTec's Commitment to Sustainability Recognized by the Dow Jones Sustainability Indices (DJSI) for the Fourth Consecutive Year
SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has been recognized by the prestigious Dow Jones Sustainability Indices ...
2024-12-30 20:00
1817
Preliminary Results of Qilu Pharmaceutical's Phase Ia Study on GPRC5D/CD3-Targeting Bispecific Antibody QLS32015 Unveiled at 2024 ASH Annual Meeting
JINAN, China, Dec. 25, 2024 /PRNewswire/ -- During the 66th Annual Meeting of the American Society of Hematology (ASH) held inSan Diego from December 7 to 10 , preliminary results from the first human trial of QLS32015, a novel anticancer drug developed by Qilu Pharmaceutical for treating relapse...
2024-12-25 15:42
2395
Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS
NANTONG and SUZHOU, China, Dec. 24, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosing of the first patient in the Phase I clinical trial of RAG-17, an innovative siRNA t...
2024-12-24 20:00
2816
Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis
CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") ofChina has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody, trade nam...
2024-12-23 22:31
1901
Porton Pharma Solutions and Dragon Sail Pharmaceutical Form Strategic Partnership to Build a New Ecosystem for ADC Drug Development, Production, and Supply Chain
CHONGQING, China, Dec. 23, 2024 /PRNewswire/ -- On December 20, 2024, Porton Pharma Solutions (hereinafter referred to as "company" or "Porton") and Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. (a subsidiary of Guilin Sanjin, hereinafter referred to as "Dragon Sail Pharmaceutical") formally si...
2024-12-23 21:00
1941
United Imaging Intelligence at RSNA 2024: Empowering a More Intelligent and Connected World with Medical AI
CHICAGO, Dec. 20, 2024 /PRNewswire/ -- As RSNA 2024 concluded, United Imaging Intelligence (UII), a subsidiary of United Imaging Group specializing in medical AI, made a significant impression with a visionary showcase that seamlessly aligned with the event's theme: "Building Intelligent Connecti...
2024-12-20 22:00
1447
Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
BOSTON, Dec. 20, 2024 /PRNewswire/ -- Medicilon, a leading preclinical contract research organization (CRO), has named Dr.Lilly Xu as its new Chief Technology Officer (CTO). With over30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon's technological innovation a...
2024-12-20 21:30
1273
Week's Top Stories
Most Reposted
COCONEXT 2024 - FIRST EVER INTERNATIONAL COCONUT CONFERENCE HOLD IN VIETNAM
[Picked up by 298 media titles]
2024-12-31 14:18
Dahua Technology Obtains ISO 37301 Compliance Management System Certification
[Picked up by 281 media titles]
2024-12-30 15:33
Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
[Picked up by 276 media titles]
2025-01-03 19:33
Russell Reynolds Associates Appoints Euan Kenworthy as Singapore Country Manager
[Picked up by 276 media titles]
2025-01-02 08:16
CKGSB Professor Mei Jianping Launches Global Indices Tracking Impressionist, Contemporary, and Chinese Art Markets
[Picked up by 258 media titles]
2024-12-31 22:30Most Read
Dahua Technology Obtains ISO 37301 Compliance Management System Certification
2024-12-30 15:33
8106
COCONEXT 2024 - FIRST EVER INTERNATIONAL COCONUT CONFERENCE HOLD IN VIETNAM
2024-12-31 14:18
8104